SORT BY

FILTER BY

also on other fortune lists

company facts

g500 stats

Global 500

Courtesy of Gilead Sciences

316

Gilead Sciences

GILD

U.S.

The California-based biotech continued its rocket-like ascent in 2015–just two years ago it ranked No. 250 on the 500–due to booming sales of its breakthrough Hepatitis C medications. Those drugs–Sovaldi and Harvoni–which cost a fortune, but also cure a chronic, devastating disease, sparked a national debate on drug pricing. They also drove Gilead’s bottom and top lines in 2015–revenues and profits jumped 31% and 50%, respectively. John Milligan, Gilead’s new CEO faces rockier road in 2016: the competition is stiffer and IP challenges and pricing pressures loom.

CEO

John F. Milligan

Sector

Health Care

Industry

Pharmaceuticals

HQ Location

Foster City, CA

Employees

8,000

Years on Global 500 List

2

Key Financials (last fiscal year)
($ Millions)% change
Revenues ($M)$32,63931.1%
Profits ($M)$18,10849.6%
Assets ($M)$51,839
Total Stockholder Equity ($M)$18,534
Profit Ratios
Profit as % of Revenues55.5%
Profits as % of Assets34.9%
Profits as % of Stockholder Equity97.7%
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Gilead Sciences

Why Cancer Biotech Allogene Just Scored an Eye Popping $324 Million IPO

The blockbuster public offering pegs Allogene's market value at more than $2 billion.

Read More →
The FDA Is Naming and Shaming Companies Accused of Blocking Cheap Generic Drugs

Celgene and Novartis are among the companies accused of thwarting generic drugs.

Read More →
Goldman Sachs: China Is Beating the U.S. in the Gene Editing Arms Race

On hot technologies like CRISPR and CAR-T, China has a leg up, Goldman says.

Read More →